Vanda Pharmaceuticals Inc. Income Statement
VNDA|15 years of annual SEC 10-K data (FY2011-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 15 fiscal years. All figures from audited SEC 10-K filings.
Vanda Pharmaceuticals Inc. reported $193M in revenue and $3M in net income for FY2025. Revenue has grown at a 30.7% compound annual rate over the past 14 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $192.6M | $254.4M | $268.7M | $248.2M | $227.2M | $193.1M | $165.1M | $146.0M | $109.9M | $50.2M | $33.9M | $32.7M | $31.3M | $35.7M | $4.5M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | $1.6M | $129.0K | $129.0K | $2.9M | $1.9M |
| Gross Profit | - | - | - | - | - | - | $42.2M | $38.7M | $33.0M | $24.4M | $17.1M | - | - | - | - |
| SG&A Expense | $112.9M | $136.5M | $124.0M | $140.5M | $129.7M | $105.8M | $123.8M | $99.8M | $84.5M | $84.6M | $25.1M | $14.5M | $11.5M | $10.1M | $23.7M |
| R&D Expense | $76.8M | $85.8M | $75.4M | $55.6M | $48.6M | $43.6M | $38.5M | $29.2M | $29.1M | $19.2M | $28.5M | $45.8M | $29.0M | $12.3M | $13.9M |
| Operating Income | -$14.0M | $6.3M | $42.2M | $27.2M | $22.8M | $21.7M | -$16.9M | -$18.6M | -$40.2M | $20.1M | -$21.2M | -$29.2M | -$10.7M | $8.8M | -$35.9M |
| Income Tax | $3.8M | $5.0M | $9.2M | $8.3M | -$86.5M | $138.0K | $136.0K | $104.0K | $104.0K | $0 | $0 | $0 | -$444.0K | $2.1M | $2.1M |
| Net Income | $2.5M | $6.3M | $33.2M | $23.3M | $115.6M | $25.2M | -$15.6M | -$18.0M | -$39.9M | $20.2M | -$21.1M | -$28.6M | -$9.8M | $7.2M | -$35.9M |
| EPS (Basic) | $0.04 | $0.11 | $0.60 | $0.43 | $2.17 | $0.50 | -$0.35 | -$0.41 | -$0.94 | $0.58 | -$0.69 | -$1.01 | -$0.35 | $0.26 | -$1.33 |
| EPS (Diluted) | $0.04 | $0.11 | $0.58 | $0.42 | $2.11 | $0.48 | -$0.35 | -$0.41 | -$0.94 | $0.55 | -$0.69 | -$1.01 | -$0.35 | $0.25 | -$1.33 |
| Shares Outstanding | 58.3M | 57.5M | 56.8M | 55.9M | 54.9M | 53.5M | 52.5M | 44.9M | 44.0M | 42.8M | 41.5M | 33.3M | 28.2M | 28.1M | 28.0M |
| Gross Margin | - | - | - | - | - | - | 25.6% | 26.5% | 30.0% | 48.6% | 50.6% | - | - | - | - |
| Operating Margin | -7.2% | 2.5% | 15.7% | 11.0% | 10.0% | 11.3% | -10.2% | -12.7% | -36.6% | 40.0% | -62.6% | -89.2% | -34.2% | 24.8% | -790.4% |
| Profit Margin | 1.3% | 2.5% | 12.3% | 9.4% | 50.9% | 13.1% | -9.4% | -12.3% | -36.3% | 40.3% | -62.2% | -87.4% | -31.4% | 20.1% | -788.5% |